vTv Therapeutics Q1 net loss $4.9M; cash rises to $52.3M on $51M placement, Phase 3 on track

vTv Therapeutics Inc.

Cash $52.3M at March 31, up from $9.4M Dec 31, after $51M private placement from healthcare investors and JDRF T1D Fund.
Net loss $4.9M ($1.17/share) vs $4.5M ($2.16/share) in Q1 2023; revenue $1.0M from milestone.
R&D spend $2.6M, down from $3.9M YoY; G&A $4.0M, up from $3.5M.
First Phase 3 cadisegliatin trial in T1D expects first patient enrollment Q2 2024, top-line data Q1 2026.
Planning two international registrational trials for cadisegliatin in T1D starting 2026; T2D Phase 2 in Middle East on track H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

vTv Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001641489-24-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.